{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:21:24Z","timestamp":1788524484860,"version":"build-2803163510"},"reference-count":123,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Myelodysplastic syndrome (MDS) are clonal myeloid neoplasms that cause cytopenias and can progress to acute myeloid leukemia (AML). Hypomethylating agents (HMA) are the mainstay of treatment for higher risk disease, but they achieve responses in only half of treated patients and complete remission rates are low. Several scientifically based combinatorial regimens have been tested in clinical trials but none has demonstrated a survival benefit over HMA monotherapy. Allogeneic stem cell transplant remains the only curative therapy and is dependent on effective donor lymphocytes for its efficacy. However, access is limited by its toxicity, so alternative approaches are sorely needed. Recent clinical and translational studies have shown that MDS is not only a clonal myeloid disorder, but also associated with immune dysregulation, inflammatory signaling, T-cell repertoire restriction, immune exhaustion, and immune mediated suppression of hematopoiesis. These findings suggest that there is potential for unlocking a novel approach to the treatment of MDS by restoring and\/or enhancing the lymphoid immune response. In this review, we discuss the current understanding of the role of normal T lymphocytes in MDS, the causes and manifestations of dysfunctional T lymphocytes as well as the role and dysfunction of natural killer (NK) cells. The role of therapeutic immunosuppression in lower risk MDS is reviewed, as is the impact of HMAs on dysregulated T lymphocytes and NK cells in higher risk disease. We propose that there is tremendous potential for more targeted approaches to engage the lymphoid compartment in addressing the unmet therapeutic need in MDS.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1907953","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:04:50Z","timestamp":1788523490000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["T lymphocytes and natural killer cells in myelodysplastic syndromes: function, dysfunction, and therapeutic potential"],"prefix":"10.3389","volume":"17","author":[{"given":"Justin","family":"Cheng","sequence":"first","affiliation":[{"name":"Keck School of Medicine, University of Southern California","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Leon","family":"Tam","sequence":"additional","affiliation":[{"name":"Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"O\u2019Connell","sequence":"additional","affiliation":[{"name":"Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: Myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26984","article-title":"Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Garcia-Manero","year":"2023","journal-title":"Am J Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"key":"B5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41408-023-00894-8","article-title":"Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification","volume":"13","author":"Lee","year":"2023","journal-title":"Blood Cancer J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01724-5","article-title":"Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): A multinational, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Platzbecker","year":"2024","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025017611","article-title":"Luspatercept for patients with lower-risk myelodysplastic syndromes\/neoplasms: A systematic review and meta-analysis","volume":"9","author":"Alhajahjeh","year":"2025","journal-title":"Blood Adv"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(23)00338-1","article-title":"Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): A registrational, randomised, crossover, pharmacokinetics, phase 3 study","volume":"11","author":"Garcia-Manero","year":"2024","journal-title":"Lancet Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012302","article-title":"Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed\/refractory myelodysplastic syndrome","volume":"8","author":"DiNardo","year":"2024","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jtct.2022.11.014","article-title":"Hematopoietic cell transplantation in the management of myelodysplastic syndrome: An evidence-based review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines","volume":"29","author":"DeFilipp","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-844654","article-title":"The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes","volume":"133","author":"Sallman","year":"2019","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-784116","article-title":"Chronic immune response dysregulation in MDS pathogenesis","volume":"132","author":"Barreyro","year":"2018","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.12.013","article-title":"Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies","volume":"122","author":"Wang","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201544","article-title":"Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS","volume":"218","author":"Trowbridge","year":"2021","journal-title":"J Exp Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v100.5.1570.h81702001570_1570_1574","article-title":"HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome","volume":"100","author":"Saunthararajah","year":"2002","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.4423249.x","article-title":"Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles","volume":"102","author":"Molldrem","year":"1998","journal-title":"Br J Haematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.272559","article-title":"Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"106","author":"Jachiet","year":"2021","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-067546","article-title":"CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)","volume":"110","author":"Kordasti","year":"2007","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2015.1062208","article-title":"Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome","volume":"5","author":"Kittang","year":"2016","journal-title":"Oncoimmunology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-035519","article-title":"Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors","volume":"109","author":"Epling-Burnette","year":"2007","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0206-4","article-title":"Human NK cells: Surface receptors, inhibitory checkpoints, and translational applications","volume":"16","author":"Sivori","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1101\/2024.03.14.585083","article-title":"Mapping the cellular biogeography of human bone marrow niches using single-cell transcriptomics and proteomic imaging","volume":"187","author":"Bandyopadhyay","year":"2024","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/moh.0000000000000621","article-title":"Structural organization of the bone marrow and its role in hematopoiesis","volume":"28","author":"Lucas","year":"2021","journal-title":"Curr Opin Hematol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41556-019-0439-6","article-title":"Combined single-cell and spatial transcriptomics reveal the molecular, cellular and spatial bone marrow niche organization","volume":"22","author":"Baccin","year":"2020","journal-title":"Nat Cell Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.10.016","article-title":"Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches","volume":"25","author":"Sugiyama","year":"2006","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/20417314241287491","article-title":"Unlocking the regenerative key: Targeting stem cell factors for bone renewal","volume":"15","author":"Karima","year":"2024","journal-title":"J Tissue Eng"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03201-2","article-title":"In situ mapping identifies distinct vascular niches for myelopoiesis","volume":"590","author":"Zhang","year":"2021","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2018.01.011","article-title":"Clonal hematopoiesis and evolution to hematopoietic Malignancies","volume":"22","author":"Bowman","year":"2018","journal-title":"Cell Stem Cell"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2012.05.015","article-title":"Signaling pathways in chronic myeloid leukemia and leukemic stem cell maintenance: Key role of stromal microenvironment","volume":"24","author":"Seke Etet","year":"2012","journal-title":"Cell Signal"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041159","article-title":"Notch signaling in vascular endothelial and mural cell communications","volume":"12","author":"O\u2019Hare","year":"2022","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nature15252","article-title":"Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6","volume":"525","author":"Zhang","year":"2015","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.118.313225","article-title":"CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease","volume":"123","author":"Sano","year":"2018","journal-title":"Circ Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"10042","DOI":"10.1038\/s41467-025-65803-y","article-title":"Inflammatory stromal and T cells mediate human bone marrow niche remodeling in clonal hematopoiesis and myelodysplasia","volume":"16","author":"Prummel","year":"2025","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","first-page":"10041","DOI":"10.1038\/s41467-025-65802-z","article-title":"An inflammatory T-cell-stromal axis contributes to hematopoietic stem\/progenitor cell failure and clonal evolution in human myelodysplastic syndrome","volume":"16","author":"Chen","year":"2025","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2034155","article-title":"Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study","volume":"63","author":"Garcia-Manero","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13287-025-04154-3","article-title":"MSCs with upregulated lipid metabolism block hematopoietic stem cell differentiation via exosomal CTP-1A in MDS","volume":"16","author":"Yin","year":"2025","journal-title":"Stem Cell Res Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2014.110","article-title":"CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes","volume":"94","author":"Abe-Suzuki","year":"2014","journal-title":"Lab Invest"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100021","article-title":"Instructive interaction between myelodysplastic hematopoiesis and the bone marrow microenvironment at the single-cell level","volume":"1","author":"Jann","year":"2024","journal-title":"Blood Neoplasia"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-255125","article-title":"Interferon-\u03b3 and tumor necrosis factor-\u03b1 induce an immunoinhibitory molecule, B7-H1, via nuclear factor-\u03baB activation in blasts in myelodysplastic syndromes","volume":"116","author":"Kondo","year":"2010","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01696-4","article-title":"Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy","volume":"28","author":"Ganan-Gomez","year":"2022","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adr0782","article-title":"Coordinated immune networks in leukemia bone marrow microenvironments distinguish response to cellular therapy","volume":"10","author":"Maurer","year":"2025","journal-title":"Sci Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2009.12.004","article-title":"Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome","volume":"38","author":"Campregher","year":"2010","journal-title":"Exp Hematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023166","article-title":"T-cell dysfunctions in myelodysplastic syndromes","volume":"143","author":"Rodriguez-Sevilla","year":"2024","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2007.03536.x","article-title":"T cell receptor Vbeta repertoire of T lymphocytes and T regulatory cells by flow cytometric analysis in healthy children","volume":"151","author":"McLean-Tooke","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/s0145-2126(01)00083-2","article-title":"Oligoclonal T cell expansion in myelodysplastic syndrome: Evidence for an autoimmune process","volume":"25","author":"Epperson","year":"2001","journal-title":"Leuk Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2009.04.009","article-title":"Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset","volume":"37","author":"Fozza","year":"2009","journal-title":"Exp Hematol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-2017","article-title":"Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome","volume":"106","author":"Sloand","year":"2005","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1365-2141.2009.07593.x","article-title":"IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome","volume":"145","author":"Kordasti","year":"2009","journal-title":"Br J Haematol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.21417\/b72d1q","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1817431","article-title":"Increased myeloid-derived suppressor cells in patients with myelodysplastic syndromes suppress CD8+ T lymphocyte function through the STAT3-ARG1 pathway","volume":"62","author":"Qi","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.288526","article-title":"Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial","volume":"111","author":"Zhou","year":"2025","journal-title":"Haematologica"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-2495","article-title":"Targeting MDSC differentiation using ATRA: A phase I\/II clinical trial combining pembrolizumab and all-trans retinoic acid for metastatic melanoma","volume":"29","author":"Tobin","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016229","article-title":"Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS","volume":"9","author":"DeZern","year":"2025","journal-title":"Blood Adv"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.02.005","article-title":"Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33\/CD3 T cell engager, ex vivo in MDS and melanoma","volume":"30","author":"Cheng","year":"2022","journal-title":"Mol Ther"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.915629","article-title":"Tumor-specific T cell-mediated upregulation of PD-L1 in myelodysplastic syndrome cells does not affect T-cell killing","volume":"12","author":"Ferrari","year":"2022","journal-title":"Front Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1865-y","article-title":"Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes","volume":"65","author":"Sand","year":"2016","journal-title":"Cancer Immunol Immunother CII"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.994053","article-title":"The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification","volume":"13","author":"Peng","year":"2022","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17837","article-title":"Immune signatures of bone marrow cells can independently predict prognosis in patients with myelodysplastic syndrome","volume":"196","author":"Wang","year":"2022","journal-title":"Br J Haematol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/cas.70405","article-title":"An immune dysfunction signature score predicts survival in MDS patients: Insights from a longitudinal, multicenter study","volume":"117","author":"Wang","year":"2026","journal-title":"Cancer Sci"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24746","article-title":"An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes","volume":"92","author":"Daher","year":"2017","journal-title":"Am J Hematol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.64","article-title":"Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium","volume":"8","author":"Tentori","year":"2024","journal-title":"HemaSphere"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1182\/blood.v106.11.3435.3435","article-title":"Clonal T cell expansion in high risk myelodysplastic syndrome (MDS)","volume":"106","author":"Painter","year":"2005","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1084\/jem.192.3.393","article-title":"Clonal expansions of Cd8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction","volume":"192","author":"Babbe","year":"2000","journal-title":"J Exp Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1810","article-title":"Safety, outcomes, and T-cell characteristics in patients with relapsed or refractory MDS or CMML treated with atezolizumab in combination with guadecitabine","volume":"28","author":"O\u2019Connell","year":"2022","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.04.007","article-title":"Myelodysplastic syndromes and autoimmune diseases--case series and review of literature","volume":"37","author":"Al Ustwani","year":"2013","journal-title":"Leuk Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2019.101136","article-title":"Autoimmune disease in CMML-the chicken or the egg","volume":"33","author":"Ambinder","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01152-1","article-title":"Genomic landscape of MDS\/CMML associated with systemic inflammatory and autoimmune disease","volume":"35","author":"Zhao","year":"2021","journal-title":"Leukemia"},{"key":"B69","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41467-023-36193-w","article-title":"Myelodysplastic syndrome associated TET2 mutations affect NK cell function and genome methylation","volume":"14","author":"Boy","year":"2023","journal-title":"Nat Commun"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018774","article-title":"Spectrum of clonal hematopoiesis in VEXAS syndrome","volume":"142","author":"Gutierrez-Rodrigues","year":"2023","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1101\/2024.05.19.594376","article-title":"Single-cell genotype-phenotype mapping identifies therapeutic vulnerabilities in VEXAS syndrome","author":"Ganesan","year":"2024"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024028216","article-title":"Impaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndrome","volume":"146","author":"Breillat","year":"2025","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq187","article-title":"Targeting of 5-aza-2\u2032-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme","volume":"38","author":"Patel","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.23.4781","article-title":"DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes","volume":"28","author":"Shen","year":"2010","journal-title":"J Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.897898","article-title":"Whole-genome DNA methylation sequencing reveals epigenetic changes in myelodysplastic syndromes","volume":"12","author":"Zhou","year":"2022","journal-title":"Front Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.099549","article-title":"Why methylation is not a marker predictive of response to hypomethylating agents","volume":"99","author":"Voso","year":"2014","journal-title":"Haematologica"},{"key":"B80","doi-asserted-by":"publisher","first-page":"490","DOI":"10.18632\/oncotarget.481","article-title":"BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients","volume":"3","author":"Cluzeau","year":"2012","journal-title":"Oncotarget"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-03932-8","article-title":"Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine","volume":"99","author":"Mart\u00edn","year":"2020","journal-title":"Ann Hematol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/35087627","article-title":"Initial sequencing and analysis of the human genome","volume":"409","author":"Lander","year":"2001","journal-title":"Nature"},{"key":"B83","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1182\/blood-2025-774","article-title":"Elucidating the role of retrotransposon-mediated viral mimicry in leukemia therapy","volume":"146","author":"Syed","year":"2025","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1038\/s41467-025-59796-x","article-title":"Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs","volume":"16","author":"Thoms","year":"2025","journal-title":"Nat Commun"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.molcel.2021.01.038","article-title":"DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells","volume":"81","author":"Loo Yau","year":"2021","journal-title":"Mol Cell"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-026-02930-5","article-title":"Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia","volume":"40","author":"Li","year":"2026","journal-title":"Leukemia"},{"key":"B87","doi-asserted-by":"publisher","first-page":"13402","DOI":"10.1038\/s41598-025-98059-z","article-title":"Maintenance therapy with Azacitidine for patients with myeloid Malignancies after allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Lu","year":"2025","journal-title":"Sci Rep"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12261","article-title":"Impact of 5\u2010aza\u20102\u2032\u2010deoxycytidine and epigallocatechin\u20103\u2010gallate for induction of human regulatory T cells","volume":"142","author":"Kehrmann","year":"2014","journal-title":"Immunology"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1172\/jci165673","article-title":"Decitabine priming increases anti\u2013PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models","volume":"133","author":"Li","year":"2023","journal-title":"J Clin Invest"},{"key":"B90","doi-asserted-by":"publisher","first-page":"659625","DOI":"10.21417\/haa2021fi","article-title":"Response to hypomethylating agents in myelodysplastic syndrome is associated with emergence of novel TCR clonotypes","volume":"12","author":"Abbas","year":"2021","journal-title":"Front Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202551796","article-title":"Comparative analysis of the TCR repertoire in bone marrow CD8+ T cells from patients with acute myeloid leukemia, myelodysplastic neoplasms, and chronic myelomonocytic leukemia","volume":"55","author":"Katsiki","year":"2025","journal-title":"Eur J Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112376","article-title":"The DNA methylation landscape across the TCR loci in patients with acute myeloid leukemia","volume":"138","author":"Pospiech","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41408-022-00615-7","article-title":"Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients","volume":"12","author":"Grimm","year":"2022","journal-title":"Blood Cancer J"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-2601","article-title":"Immunologic predictors for clinical responses during immune checkpoint blockade in patients with myelodysplastic syndromes","volume":"29","author":"Lee","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100106","article-title":"Checkpoint immunotherapy is associated with preferential activation of tumor antigen\u2013specific CD4+ T cells in MDS","volume":"2","author":"Griffiths","year":"2025","journal-title":"Blood Neoplasia"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.02.020","article-title":"Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis","volume":"31","author":"Rohner","year":"2007","journal-title":"Leuk Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6213","article-title":"Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome","volume":"6","author":"Sohlberg","year":"2015","journal-title":"Oncotarget"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2010.04.002","article-title":"In vitro deprivation of CD8(+)CD57(+)T cells promotes the Malignant growth of bone marrow colony cells in patients with lower-risk myelodysplastic syndrome","volume":"38","author":"Zheng","year":"2010","journal-title":"Exp Hematol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/s0145-2126(02)00173-x","article-title":"Determination of T-cell receptors of clonal CD8-positive T-cells in myelodysplastic syndrome with erythroid hypoplasia","volume":"27","author":"Matsutani","year":"2003","journal-title":"Leuk Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3325","article-title":"A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome","volume":"102","author":"Saunthararajah","year":"2003","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0155","article-title":"Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression","volume":"100","author":"Kochenderfer","year":"2002","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018019414","article-title":"The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-277921","article-title":"T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy","volume":"117","author":"Sloand","year":"2011","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3324\/haematol.13612","article-title":"Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome","volume":"94","author":"Chamuleau","year":"2009","journal-title":"Haematologica"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.950134","article-title":"Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate\/high-risk myelodysplastic syndromes under hypomethylating treatment","volume":"13","author":"Geng","year":"2022","journal-title":"Front Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286559","article-title":"A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome","volume":"110","author":"Bouligny","year":"2025","journal-title":"Haematologica"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1126\/science.adl4492","article-title":"Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy","volume":"386","author":"Kang","year":"2024","journal-title":"Science"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17461","article-title":"Myelodysplastic syndrome patients display alterations in their immune status reflected by increased PD-L1-expressing stem cells and highly dynamic exhausted T-cell frequencies","volume":"193","author":"Moskorz","year":"2021","journal-title":"Br J Haematol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2017.01.006","article-title":"Tim3\/Gal9 interactions between T cells and monocytes result in an immunosuppressive feedback loop that inhibits Th1 responses in osteosarcoma patients","volume":"44","author":"Li","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13488","article-title":"TIM3\/CEACAM1 pathway involves in myeloid-derived suppressor cells induced CD8+ T cells exhaustion and bone marrow inflammatory microenvironment in myelodysplastic syndrome","volume":"168","author":"Yu","year":"2023","journal-title":"Immunology"},{"key":"B111","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1182\/blood-2021-146039","article-title":"Efficacy and safety of Sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high\/high-risk myelodysplastic syndrome (vHR\/HR-MDS) and acute myeloid leukemia (AML): Final analysis from a Phase Ib study","volume":"138","author":"Brunner","year":"2021","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v118.21.2808.2808","article-title":"T cells of patients with myelodysplastic syndrome are frequently derived from the Malignant clone","volume":"156","author":"Vercauteren","year":"2012","journal-title":"Br J Haematol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1046\/j.1365-2141.2001.02561.x","article-title":"Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features","volume":"112","author":"Saunthararajah","year":"2001","journal-title":"Br J Haematol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.leukres.2016.02.006","article-title":"T-cell large granular lymphocyte proliferation in myelodysplastic syndromes: Clinicopathological features and prognostic significance","volume":"43","author":"Zhang","year":"2016","journal-title":"Leuk Res"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0601-y","article-title":"Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome","volume":"34","author":"Durrani","year":"2020","journal-title":"Leukemia"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1309\/ajcp6yhi1jexawap","article-title":"T-cell large granular lymphocyte leukemia associated with myelodysplastic syndrome: a clinicopathologic study of nine cases","volume":"131","author":"Huh","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1114885","article-title":"Somatic STAT3 mutations in large granular lymphocytic leukemia","volume":"366","author":"Koskela","year":"2012","journal-title":"N Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-494930","article-title":"STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients","volume":"122","author":"Jerez","year":"2013","journal-title":"Blood"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25267","article-title":"Mutations and karyotype predict treatment response in myelodysplastic syndromes","volume":"93","author":"Idossa","year":"2018","journal-title":"Am J Hematol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006721","article-title":"Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells","volume":"137","author":"Pastoret","year":"2021","journal-title":"Blood"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005831","article-title":"Frequent somatic TET2 mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias","volume":"138","author":"Olson","year":"2021","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci Transl Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1907953\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:04:52Z","timestamp":1788523492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1907953\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":123,"alternative-id":["10.3389\/fimmu.2026.1907953"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1907953","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1907953"}}